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Malaria is a major global health problem, with severe mortality in children living in
sub-Saharan Africa, and there is currently no licensed, effective vaccine. However, vaccine-
induced protection from Plasmodium infection, the causative agent of malaria, was
established for humans in small clinical trials and for rodents in the 1960s. Soon after,
a critical role for memory CD8 T cells in vaccine-induced protection against Plasmodium
liver-stage infection was established in rodent models and is assumed to apply to humans.
However, these seminal early studies have led to only modest advances over the ensuing
years in our understanding the basic features of memory CD8 T cells required for
protection against liver-stage Plasmodium infection, an issue which has likely impeded the
development of effective vaccines for humans. Given the ethical and practical limitations in
gaining mechanistic insight from human vaccine and challenge studies, animal models still
have an important role in dissecting the basic parameters underlying memory CD8 T-cell
immunity to Plasmodium. Here, we will highlight recent data from our own work in the
mouse model of Plasmodium infection that identify quantitative and qualitative features of
protective memory CD8 T-cell responses. Finally, these lessons will be discussed in the
context of recent ﬁndings from clinical trials of vaccine-induced protection in controlled
human challenge models.
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INTRODUCTION
Malaria represents an enormous global health problem. It is asso-
ciated with around 200 million reported annual cases and more
than 600,000 deaths,most of them recorded in sub-SaharanAfrica
(WHO, 2011). Current disease treatment is limited to antimalar-
ial drugs targeting the symptomatic blood-stage infection. Given
the enormous genetic plasticity of the parasite, the emergence of
antimalarial drug resistance is inevitable and thus a major con-
cern (Miller et al., 2013). Hence, the development of a protective
malaria vaccine is alarmingly urgent.
Blocking Plasmodium infection at the level of the silent, liver
stage of malaria represents an attractive strategy for disease
prevention (Kappe et al., 2010). The earliest evidence of vaccine-
induced, sterile, liver-stage immunity originates from mouse
studies, in which it was demonstrated that vaccination with radi-
ation attenuated sporozoites (RAS) prevented development of
blood-stage Plasmodium berghei infection after sporozoite chal-
lenge (Nussenzweig et al., 1967, 1969). Importantly, RAS-induced
sterile protection was conﬁrmed in human subjects, in whom it
was induced upon exposure to bites of more than 1000 sporozoite-
bearing, irradiated mosquitoes (Clyde et al., 1973; Edelman et al.,
1993; Hoffman et al., 2002). Persistent efforts to repeat the success
of RAS in inducing sterilizing immunity using different vaccine
formulations and regimens (e.g., which are easier to manufacture
and can be administered through approved vaccination routes)
have led only to a partial success (Moorthy et al., 2004; Dunachie
et al., 2006; Bejon et al., 2007; Moorthy and Ballou, 2009; Agnandji
et al., 2012). Therefore, RAS immunization still represents the gold
standard for induction of sterile protection and, despite logistical
challenges, has moved recently to Phase I clinical trial.
Besides being a potential vaccine candidate, RAS has been used
as an invaluable tool for studying protective immune responses
against liver-stage Plasmodium infections. Although the earliest
work describes neutralizing antibodies as the main mechanism
of RAS-induced protection (Potocnjak et al., 1980; Yoshida et al.,
1980), more recently depletion studies and adoptive-transfer
experiments have demonstrated that CD8 T cells have a lead-
ing role in protection against sporozoite challenge (Schoﬁeld
et al., 1987; Weiss et al., 1988; Rodrigues et al., 1991). The criti-
cal role of CD8 T cells in protection against liver-stage malaria has
been conﬁrmed upon immunization with different formulations,
such as recombinant vaccines [e.g., Salmonella typhimurium, vac-
cinia virus or adeno virus expressing P. berghei circumsporozoite
(CS) protein] and genetically attenuated parasite (GAP; Sadoff
et al., 1988; Lanar et al., 1996; Rodrigues et al., 1997; Jobe et al.,
2007).
Despite the strong evidence for the role of CD8 T cells in ster-
ile protection against malaria, critical qualitative and quantitative
characteristics of the protective response and effector mechanisms
engaged by CD8 T cells remain incompletely understood. The
modest progress in this ﬁeld is strongly inﬂuenced by the extreme
genetic plasticity of the parasite, its complex life cycle and the
paucity of deﬁned antigenic targets for CD8 T cells. Filling these
knowledge gaps is of an utmost importance, as this information
would facilitate the development of successful pre-erythrocytic
vaccine candidates.
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Although highly desirable, studies of Plasmodium infection
in humans are limited by multiple ethical and practical factors
(inability to manipulate the immune response for mechanistic
studies, difﬁculty to access relevant samples, etc.). Therefore,
progress in understanding immunity against liver-stage malaria
critically depends on the availability of suitable animal models.
Infection of mice with P. berghei and Plasmodium yoelii, two
rodentPlasmodiumpathogens, closely resembles the early stages of
human liver invasion, replication, and development within hep-
atocytes (Meis et al., 1983; Sturm et al., 2006; Baer et al., 2007).
Additionally, clear differences in infectivity and pathogenicity dis-
played by these two Plasmodium species mimic the diversity of
human Plasmodium infections (Sedegah et al., 2007). Therefore,
themousemodel has proven to be invaluable for basic studies, such
as host–parasite interactions and the underpinning of the immune
mechanisms driving protection induced upon vaccination and
sporozoite inoculation.
Here, we will present and highlight lessons about protective
memoryCD8T-cell thresholds for liver-stage protection and effec-
tor mechanisms engaged by these cells, learned from vaccinations
of mice with both subunit (Plasmodium CS-derived epitope) and
whole-parasite (RAS and GAP) vaccine formulations. Finally,
we will discuss the outcomes of recent vaccine clinical trials in
light of our own ﬁndings and highlight the implications of the
lessons learned for further development of liver-stage malaria
vaccines.
INDUCTION OF CD8 T CELLS BY SUBUNIT VACCINES
SETTING THE NUMERIC THRESHOLD
Induction of sterilizing immunity against liver-stage parasite rep-
resents a challenge for at least two reasons. First, liver-residing or
recruited CD8 T cells have to locate and eliminate all the infected
hepatocytes/parasites to prevent progression of the infection from
the liver to the blood stage. A single mosquito bite delivers a few
hundred infectious sporozoites into the skin dermis. Given that
only a fraction of sporozoites actually reaches the liver and infects
hepatocytes, we estimate that only 1 out of 109 hepatocytes in
humans or 1 out of 106 hepatocytes in mice are infected after
mosquito infection. Similarly, low frequencies of infected hepa-
tocytes are likely after intravenous (i.v.) challenge with 100–1000
virulent sporozoites, as used inmanymouse studies. Thus, survey-
ingCD8T cells target extremely rare events, creating the proverbial
“needle in a haystack” scenario. Second, the time interval between
the start of the liver-stage infection and release of blood-stage
merozoites is very short (7 days in Plasmodium falciparum and
2 days in P. berghei/P. yoelii), which means that CD8 T cells have a
limited amount of time to perform their task (Sturm et al., 2006;
Sturm and Heussler, 2007; Todryk and Hill, 2007). In the con-
text of these spatial and temporal pressures, it is important to
gain knowledge about the quantitative and qualitative features of
protective memory CD8 T-cell response.
To address these questions, we used a mouse model to induce a
stable, long-lastingmemory CD8 T-cell response against a deﬁned
epitope (P. berghei CS252−260). For this purpose, we exploited an
accelerated prime-boost approach that is well established in our
laboratory (Badovinac et al., 2005). In short, mice were vaccinated
with mature dendritic cells (DCs), which had been incubated for
2 h with CS-derived peptide to allow surface peptide–MHC com-
plexes to form (DC-CS), and a week later they received a booster
vaccination with an attenuated Listeria monocytogenes expressing
the same CS-derived peptide (LM-CS; Schmidt et al., 2008). This
vaccination strategy (from here on abbreviated as DC-LM) has
proven to be a robust tool for the generation and study of stable,
long-lasting memory CD8 T-cell response against deﬁned anti-
genic determinants without contribution by other components of
the immune response (CD4 T cells, antibodies, NK cells; Schoﬁeld
et al., 1987; Weiss et al., 1993; Doolan and Hoffman, 1999, 2000).
This vaccination approach allowed us to induce CS-speciﬁc
CD8 T-cell immune responses with a magnitude of 1–7% of the
total peripheral blood leukocytes (PBLs) (up to 20% of CD8 T
cells). Strikingly, this response was stable and protective against
repeated sporozoite challenges for at least 19 months (the life
span of a laboratory mouse). Moreover, by titrating the booster
vaccine dose, we were able to induce CD8 T-cell response with
decreasing magnitude, which allowed us to determine the poten-
tial numeric threshold required for protection. Strikingly, we
observed that more than 95% of animals with CD8+ T-cell fre-
quencies exceeding a threshold of 1% of total PBLs were protected
against sporozoite challenge, whilemore than 95%of animals with
CD8 T-cell frequencies below this threshold developed blood-
stage infection and were thus not sterilely protected (Schmidt
et al., 2008). These ﬁndings demonstrate that sterile protection
against sporozoite infection requires a remarkably strong CD8
T-cell response, representing a substantial fraction of the total CD8
T-cell pool and highly exceeding frequencies of antigen-speciﬁc
CD8 T cells required for plausible protection against various viral
and bacterial infections (Schmidt et al., 2008). On the other hand,
given the previously mentioned spatial and temporal pressures on
the sterilizing CD8 T-cell-mediated response, these results do not
come as a complete surprise. It is not difﬁcult to imagine that
recognition and elimination of all the rare infected hepatocytes
within 2 days require mobilization of extremely high CD8 T-cell
numbers.
Thus, we describe a quantitative feature of protective memory
CD8T-cell response against liver-stagePlasmodium, and show that
if met, this feature can potentially ensure life-long protection.
DISSECTING EFFECTOR FUNCTIONS UTILIZED BY PROTECTIVE
MEMORY CD8 T CELLS
Various effector molecules, such as IFN-γ, TNF-α, perforin,
FasL, and TRAIL, are utilized by memory CD8 T cells in pro-
tection against different infections (Raeder et al., 2000; Trapani
and Smyth, 2002; Shrestha et al., 2006, 2008; Ishikawa et al.,
2009). A few attempts were made to deﬁne the effector compo-
nent of the CD8 T-cell responses against liver-stage Plasmodium
infections. As these studies were based on RAS immunizations,
which in addition to CD8 T-cell responses also induce also CD4
T cell and antibody responses, it is still not completely clear
which pathways are engaged by memory CD8 T cells (Ferreira
et al., 1986; Schoﬁeld et al., 1987; Tsuji et al., 1995; Renggli et al.,
1997; Rodrigues et al., 2000). Furthermore, it is not clear whether
CD8 T-cell responses against different Plasmodium species require
the same effector pathways for sterile immunity. This infor-
mation is of high relevance for the development of human
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vaccines,whichwould ideally protect againstmultiplePlasmodium
species.
To study effector functions in well-deﬁnedmemory CD8 T-cell
population, we used the DC-LM prime/boost approach. In con-
trast to vaccination with whole-parasite formulations, which in
addition to CD8 T cells elicit also non-CD8 T-cell responses, this
immunization approach allows focus only on effector pathways
utilized by memory CD8 T cells (Schmidt et al., 2009). Memory
CD8 T-cell responses against P. beghei and P. yoelii CS-derived
peptides were induced in wild-type (wt) BALB/c mice together
with mice deﬁcient for various effector molecules (IFN-γ, per-
forin, FasL, and TRAIL). Additionally, TNF-α was depleted by
neutralizing antibodies in vaccinated, wt mice to assess its role in
CD8 T-cell-mediated sterile protection.
The most important ﬁnding of the study was that the pathways
of memory CD8 T-cell-mediated protection against liver-stage
infection were not completely overlapping for the two differ-
ent Plasmodium species (Butler et al., 2010). Protection against
P. berghei was diminished in the absence of IFN-γ and TNF-α
but was not inﬂuenced by the absence of perforin. In contrast,
the absence of perforin, but not TRAIL and FasL, completely
eliminated protection against P. yoelii. In line with this ﬁnd-
ing, induction of generalized inﬂammation by treatment of
animals with TLR9 agonist (CpG) 24 h-post sporozoite infec-
tion was sufﬁcient to block the progression of P. berghei, but
not P. yoelii infection to the blood stage. Susceptibility of P.
yoelii sporozoites to CpG-induced inﬂammation was observed
only during a very short window of 12 h-post infection. As
P. yoelii displays higher infectivity in rodents compared to P.
berghei (Sedegah et al., 2007), it is likely that more stringent con-
trol of parasite replication and development, involving direct
killing of infected hepatocytes through the perforin pathway,
are required for successful control of this infection at the liver
stage.
Thus, effector mechanisms exploited by memory CD8 T cells
in protection against liver-stage infection are Plasmodium species
speciﬁc, a ﬁnding of high relevance for development of protective
human vaccine targeting clinically relevant P. falciparum and P.
vivax.
INFLUENCE OF Plasmodium–HOST INTERACTIONS ON MEMORY CD8
T-CELL-MEDIATED PROTECTION AGAINST LIVER-STAGE Plasmodium
INFECTION
Although we demonstrated a clear threshold (>1% of PBL) for
CD8 T-cell-mediated sterilizing immunity, our ﬁndings were lim-
ited to one mouse strain (BALB/c) and one Plasmodium species
(P. bergei; Schmidt et al., 2008). The observation that some mouse
strains, e.g., C57Bl/6 and B10.D2, are more difﬁcult to protect
against sporozoite infection upon RAS vaccination than BALB/c
(Weiss et al., 1989; Doolan and Hoffman, 2000) made us wonder
to what extent the protective threshold is inﬂuenced by host–
parasite interactions deﬁned by host-strain-speciﬁc background
genes. Multiple studies have acknowledged the important role
of non-MHC-linked host background genes on development of
an immune response against infections (Hsieh et al., 1995; Diosi,
2002). Of equal importance, human malaria is caused by infec-
tion with multiple Plasmodium species, thus raising the question
to what extent the protective threshold is inﬂuenced by different
parasite species.
In our hands, following the DC-LM prime/boost with P. yoelii
CS280−288, mice developed high-magnitude memory CD8 T-cell
responses that exceeded the deﬁned threshold established with
P. berghei model (>1% of total PBL). Interestingly, unlike our
observations after P. berghei infection, these animals were highly
susceptible even to a low-dose, P. yoelii challenge (Schmidt et al.,
2011). Although we were able to substantially increase the size of
memory CD8 T-cell population (>1.5% of total PBL), we were
unable to ﬁnd a deﬁned, numerical threshold required for stable
(deﬁned as>80%) protection against liver-stage infection with P.
yoelii. This observation was in line with the ﬁnding that protec-
tion against P. yoelii infection requires more stringent control of
parasite replication, achieved by direct killing of infected hepato-
cytes by engagement of the perforin pathway (Butler et al., 2010).
Thus, the protective memory CD8 T-cell threshold was highly
inﬂuenced by the species of Plasmodium even in a single mouse
strain.
In parallel with this, we observed that different strains of
mice expressing the same MHC class I molecule (H-2Kd) that
presents the CS-epitopes, but differing in background genes, dis-
play dramatically different levels of susceptibility to P. berghei
sporozoite challenge (Figure 1). Importantly, in all these mouse
strains, the DC-CS/LM-CS vaccination induced memory CD8
T-cell responses of similar magnitude and quality (e.g., pro-
duction of IFN-γ; Schmidt et al., 2011). While more than 80%
of immunized BALB/c and DBA/2 mice were protected against
the infection, protection observed in mice with C57Bl/6 or
closely related C57Bl/10 background genes (CB6F1 and B10.D2,
respectively) was marginal or completely absent. Only after
administration of a second booster vaccination dose, which
induced extremely high-magnitude memory CD8 T-cell response
(∼15% of the total PBL or ∼60% of the total CD8+ T cells),
were B10.D2 and CB6F1 mice protected from sporozoite chal-
lenge. Furthermore, a study performed on reciprocal bone
marrow chimeras between B10.D2 and BALB/c mice revealed
that B10.D2 T-cell immune response reconstituted on a BALB/c
background displays a superior protection in comparison to
BALB/c T-cell response reconstituted on C57Bl/10 background.
All the evidence results suggest that it is not the functional
or quantitative property of memory CD8 T-cell response, but
rather the host–pathogen interactions, determined by the host-
background gene milieu and parasite species, that are key fac-
tors determining thresholds for memory CD8 T-cell-mediated
protection. Of note, we have not identiﬁed a mouse back-
ground that is easier to protect against Plasmodium sporozoite
infection.
This knowledge obtained in a mouse malaria model is of a
particular relevance for understanding differences in protection
observed in heterogeneous human populations and for devel-
opment of successful malaria vaccines, which have to ensure
protection against multiple, human Plasmodium species. Given
the modest success of current human vaccines in inducing CD8
T-cell response, the extremely high numerical requirements for
sterile protection against malaria may be an additional challenge
for vaccine development.
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FIGURE 1 | Numerical thresholds required for memory CD8
T-cell-mediated sterilizing protection from sporozoite challenge:
influence of host background genes and Plasmodium strain.
Sterilizing protection of BALB/c mice against P. berghei or P. yoelii
requires numbers of antigen- (CS-derived epitope) speciﬁc memory
CD8 T-cell equivalent to ∼1% or 2% of total PBLs, respectively.
Sterilizing protection of mice with C57Bl/6 background requires
substantially higher CD8 T-cell numbers: ∼8% of total PBLs in the
case of P. berghei infection, or ∼13% in the case of P. yoelii
infection.
INFLUENCE OF UNRELATED INFECTIONS ON MAINTENANCE OF
Plasmodium-SPECIFIC MEMORY CD8 T CELLS AND PROTECTION
In the parts of the world where malaria is endemic, infections
with various, malaria-unrelated pathogens are also very common
(Corbett et al., 2006; Magambo et al., 2006; Hotez and Kamath,
2009). Therefore, it is very likely that the burden of multiple
infections has a substantial impact on the maintenance of both
numbers and quality of Plasmodium-speciﬁcmemory CD8T cells,
the major mediators of protection against liver-stage infection
(Selin et al., 1996, 1999;Welsh and Selin, 2009). The phenomenon
of attrition of antigen-speciﬁc memory CD8 T-cell populations
has been described earlier in the context of infections with unre-
lated viruses (Selin et al., 1996, 1999). Speciﬁcally, these authors
showed that antigen-speciﬁcmemory CD8 T cells induced inmice
by exposure to a viral infection underwent a decrease in frequency
and numbers upon subsequent infection with unrelated viruses.
Investigating to which extent memory CD8 T cells are affected
by unrelated infections and whether this potential effect can be
reversed is of high relevance as it may provide basic informa-
tion about development and reshaping of Plasmodium-speciﬁc
immune response and useful guidelines for development of
successful vaccine regimens.
In a separate study, we showed that exposure of mice to
infections with unrelated pathogens (e.g., LCMV, LM, VacV,
MHV-1) following DC-LM CS prime/boost vaccination induces
dramatic decreases in frequency, but also in total numbers of
antigen-speciﬁc memory CD8 T cells (Schmidt and Harty, 2011).
Furthermore, more pronounced overall attrition was observed
in the subpopulation of effector memory (Tem) compared to
central memory (Tcm) T cells. This change in subset com-
position may have substantial functional consequences, as we
previously suggested that Tem, but not Tcm are closely corre-
lated with protection against sporozoite challenge (Schmidt et al.,
2010). These drastic changes in numbers and composition of
antigen-speciﬁc memory CD8 T-cell subsets resulted in seriously
compromisedprotection, as only 10%of immunizedmice exposed
to malaria-unrelated infections were protected against sporozoite
challenge. Importantly, the induced attrition did not hamper
the capacity of memory CD8 T cells to expand upon antigen
re-encounter. In line with this, a single-booster immunization
after virus-induced attrition induced expansion of the memory
population and restored the subpopulation structure (Tem vs.
Tcm), and, most importantly, the protection against sporozoite
challenge.
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As multiple pathogens are endemic to the same geographic
areas as malaria, it is very likely that vaccination-induced mem-
ory CD8 T-cell response will undergo a certain degree of attrition,
which poses an additional concern for successful vaccination. The
ﬁnding that despite the attrition, memory CD8 T cells remain
responsive to booster vaccination, suggests that the use of prime
and regular booster vaccination approach may be critical to
preserve long-term immunity against malaria.
INDUCTION OF CD8 T CELLS BY WHOLE-PARASITE VACCINES
BROADENING OF THE ANTIGEN REPERTOIRE BY VACCINATION WITH
RAS: IMPACT ON NUMERICAL THRESHOLDS
To date, only two immunization approaches have demonstrated
a capacity to induce sterile protection against liver-stage malaria
in both humans and animal models. Recently, an immunization
approach based on multiple, low-dose inoculations of wt sporo-
zoites through mosquito bites in individuals were also continually
treatedwith the antimalarial drug chloroquine drugwas evaluated.
This approach was shown to successfully protect humans from a
subsequent mosquito bit challenge (Roestenberg et al., 2011). The
second approach is RAS vaccination,which still represents the gold
standard of antimalarial protection (Clyde et al., 1973; Edelman
et al., 1993; Hoffman et al., 2002). Nevertheless, critical parame-
ters of protection, such as quantity and quality of the RAS-induced
memory CD8 T-cell remain unknown.
After establishing that sterile immunity against sporozoite chal-
lenge in mice vaccinated with a single Plasmodium CS epitope
requires mobilization of a large portion of total memory CD8+
T-cell pool (Schmidt et al., 2008), we decided to probe the hypoth-
esis that broadening the antigenic targets would decrease the
threshold of memory CD8 T cells required for protection. Multi-
ple, low-magnitude, immune responses against broad range of
antigenic determinants may have a superior protective capac-
ity in comparison to monospeciﬁc response. For this purpose,
the RAS vaccination regime was applied (Schmidt et al., 2010).
To overcome the lack of well-deﬁned MHC class I-restricted
antigenic determinants, we took advantage of a surrogate acti-
vation marker approach recently described by our laboratory for
measuring CD8 T-cell responses to bacterial or viral pathogens
(Rai et al., 2009). Activation of effector or memory antigen-
speciﬁc CD8 T cells by exposure to viral or bacterial infection
induces down regulation of CD8α and up-regulation of CD11a.
Importantly, these changes are stable in well-deﬁned, antigen-
speciﬁc CD8 T cells for the life of the laboratory mouse. This
approach allowed us for the ﬁrst time to follow and quantitatively
and qualitatively characterize RAS-speciﬁc memory CD8 T-cell
response and to assess the induced protection in multiple mouse
strains.
To our surprise, broadening of the CD8 T-cell antigenic reper-
toire by vaccination with RAS did not measurably decrease the
numerical threshold of memory cells required for protection
(Schmidt et al., 2010). As shown by speciﬁc antibody depletion
studies, the protection depended on CD8 T cells but not CD4
T cells (Schmidt et al., 2010). Similarly to our results with CD8
T cells speciﬁc for CS-derived epitopes, sterile protection was
highly dependent on the mouse strain and Plasmodium species
(Figure 1). Thus, BALB/c mice were relatively “easy” to protect,
as a single dose (20,000) of RAS was sufﬁcient to induce ster-
ile protection against P. berghei challenge in > 80% of animals,
and a single-booster immunization ensured protection against
highly virulent P. yoelii challenge. On the other hand, protec-
tion observed in C57Bl/6 mice after a single RAS immunization
was absent, despite similar memory CD8 T-cell numbers induced
upon vaccination in both mouse strains. Solid, sterile protection
of these mice against P. berghei sporozoite challenge requiredmul-
tiple booster doses and multiple-fold increase in the magnitude of
the CD8 T-cell response. Antigen-speciﬁc CD8 T-cell populations
representing even 40% of total CD8 T cells in B6 mice were not
sufﬁcient to protect against P. yoelii challenge at a memory time
point.
Importantly, application of surrogate activation markers
allowed us for the ﬁrst time to follow and characterize RAS-
speciﬁc memory CD8 T-cell responses and subsequent protection
in populations of outbred mice, which may be a better model
for genetically diverse human populations. In striking contrast to
more or less uniform memory CD8 T-cell responses induced in
inbred mice, responses measured in outbred groups varied sub-
stantially in magnitude and kinetics among individual animals.
Despite wide distribution of immune responses,>80% of prime-
boosted outbredmice were sterilely protected against homologous
challenge with P. berghei and P. yoelii sporozoite infection. Impor-
tantly, this ﬁnding could potentially predict the distribution of
immune responses uponwhole-parasite immunization at the level
of heterogeneous human populations.
MULTIPLE BENEFITS FROM TARGETING LATE-LIVER-STAGE ANTIGENS
Recently, a new sporozoite attenuation strategy has been devel-
oped, based on a direct manipulation (deletion) of target parasite
genes (Mueller et al., 2005b). Such a targeted attenuation method
may be superior in comparison to irradiation. While irradiation
induces random lesions in DNAmolecules and consequently gives
rise to genetically diverse population of RAS, geneticmanipulation
allows for controlled production of well-deﬁned and geneti-
cally similar parasites (genetically attenuated parasites – GAP;
Chattopadhyay et al., 2009; Kappe et al., 2010). Additionally, while
attenuation by irradiation arrests the parasite development at an
early liver stage (Menard et al., 2013), targeting speciﬁc genes cru-
cial for various metabolic processes allows for more or less custom
design of GAP and production of both early- and late-liver-stage-
arresting parasites (Mueller et al., 2005a,b; Aly et al., 2008). GAP
have been tested in multiple pre-clinical studies and induced CD8
T-cell-mediated protection in murine malaria models (Labaied
et al., 2007; Tarun et al., 2007).
Given the different degrees of intrahepatic development
between early-liver-stage-arrested RAS and GAP and late-liver-
stage-arrested GAP, we hypothesized that the latter expresses a
broader spectrum of antigen determinants, and possibly induces
superior protection. Consistent with this notion, vaccination
with late-liver-stage-arrested GAP induced higher memory CD8
T-cell responses, which closely correlated with better protection
induced in BALB/c, but also C57Bl/6 and Swiss Webster mice
(Butler et al., 2011). Importantly, the antigenic speciﬁcity of the
memory CD8 T-cell immune responses induced by early- and
late-liver-stage-arresting vaccines was only partially overlapping.
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From our study, it was clear that late-liver-stage-arresting GAP
induce responses against broader spectrum of antigens compared
to both RAS and early-liver-stage-arrested GAP. Thus, we con-
cluded that superior protection induced upon vaccination with
late-liver-stage-arrested GAP was based on the broadening of the
antigenic repertoire.
These ﬁndings are particularly important in the light of recent
ﬁnding of Tarun et al. (2008), who predicted that late-liver-stage
and blood-stage parasites have substantial overlap in their antigen
pools. This would mean that vaccination with late-liver-stage-
arrestedGAPmay also induce cross-stage protection. Indeed,mice
vaccinatedwith high numbers of late-liver-stage-arrestedGAP,but
not RAS, displayed high degree of protection against both liver-
and blood-stage challenge (Butler et al., 2011).
Targeting a broad spectrum of antigens, particularly the ones
shared by different developmental stages of the parasite, may
increase the protective efﬁcacy of a vaccine (Table 1). Not only
do late-liver-stage-arrested GAP represent a promising vaccine
candidate, but these parasites may also serve as an important
model for determining novel CD8 T-cell antigens, which might be
exploited for design of new generation of cross-protective subunit
vaccines.
OUTCOME OF RECENT HUMAN TRIALS: NUMBERS DO
MATTER
Although a substantial body of evidence has been collected
pointing to the relevance of CD8 T-cell response in control-
ling liver-stage malaria, current vaccines have displayed rather
modest capacity of inducing such responses in humans. The
most advanced malaria vaccine is RTS,S, a subunit vaccine
based on CS protein, which induces partial protection that
correlates with antibody and CD4 T-cell immune responses,
but no detectable CD8 T-cell response (Moorthy and Bal-
lou, 2009). In the most recent ﬁeld clinical trial in children
this vaccine displayed ∼30% efﬁcacy against clinical malaria
in the target population of 6–12-month-old infants (Agnandji
et al., 2012). Thus, there is a need for development of new
vaccine candidates with the capacity to elicit CD8 T-cell
response, and which can be used alone or in combination with
RTS,S.
One of the promising CD8 T-cell-inducing approaches is
based on heterologous prime-boost strategies using different viral
vectors expressing the same CD8 T-cell-target antigens (Hill et al.,
2010). Unfortunately, most of the vaccination regimens that were
successful inmice failedwhen tested inhumans (Ockenhouse et al.,
1998; Moorthy et al., 2004; Bejon et al., 2006, 2007). Recently, a
new promising prime-boost regimen based on chimpanzee ade-
novirus/MVA expressing Plasmodium thrombospondin adhesive
protein (TRAP) fused to a multiple epitopes derived from sev-
eral malaria antigens has been successfully tested in pre-clinical
studies (Colloca et al., 2012), followed by two clinical trials in
humans (O’Hara et al., 2012; Ewer et al., 2013). Results of the
Phase IIa clinical trial revealed that 20% of vaccinated sub-
jects had sterilizing immunity against standardized sporozoite
infection, and 35% of vaccines displayed signiﬁcant delay to a
patency, which represent an additional measure of vaccine efﬁ-
cacy (Ewer et al., 2013). Although the degree of protection was
modest, a very important ﬁnding of the study was the close
correlation between the observed protection and the increased
percentage of total CD8 T cells producing vaccine antigen-speciﬁc
IFN-γ, over that induced in previous vaccine trials. Moreover,
the efﬁciency of protection (sterile protection vs. delay to a
patency vs. lack of protection) was dependent on the magni-
tude of IFN-γ-producing CD8 T cells, suggesting the existence
of protective threshold, which is in line with our ﬁnding in a
mouse model. The existence of protective CD8 T-cell thresh-
olds may explain the failure of previous vaccination regimens
tested in humans (Schmidt et al., 2008, 2010). On the other hand,
it remains possible that protective memory CD8 T-cell thresh-
olds in humans may be lower (<0.3% of total CD8 T cells)
than those we observed in mice (>15% of total CD8 T cells).
One of the possible explanations is the prolonged intra-hepatic
phase of sporozoite infection in humans (6–8 days), compared
to mice (2 days), providing human CD8 T cells with substan-
tially more time for detection and elimination of infected cells,
which might decrease the cell numbers required for successful
protection.
Another recent human trial conﬁrmed the importance of
magnitude of CD8 T-cell response in protection against liver-
stage malaria. Although it has been known for four decades
that vaccination of human subjects with RAS via mosquito bites
induces sterile protection against subsequent sporozoite challenge,
only recently the ﬁrst aseptic, radiation-attenuated, metabolically
active, puriﬁed, cryopreserved, sporozoite vaccine was tested in
a clinical trial, when it was injected into human subjects via
two standard vaccination routes: subcutaneous (s.c.) and intra-
dermal (i.d.; Epstein et al., 2011). Interestingly, the result of
this ﬁrst RAS clinical trial was the absence of protection in all
the subjects, regardless of the dose received. With the hypoth-
esis that the failure in protection was due to the suboptimal
vaccination route rather than to lack of vaccine immunogenic-
ity, Seder et al. (2013) performed another clinical trial using the
Table 1 | Comparison between early- and late-liver stage arresting whole-sporozoite vaccines.
Vaccine Mode of
inactivation
Stage of arrest Percentage of
sterilizing protection






RAS Irradiation Early liver 5 No Partial
sap1− GAP Mutagenesis Early liver 20 No –
fabb− GAP Mutagenesis Late liver 40 Yes Yes
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intravenous (i.v.) route for the vaccine delivery. The hypothesis
was initially tested and conﬁrmed in both non-human primate
and a mouse model, as which revealed that i.v. immunization
with RAS induces superior protection against sporozoite chal-
lenge when compared to s.c. immunization (Epstein et al., 2011).
Using the previously described surrogate activation markers to
enumerate antigen-speciﬁc CD8 T cells, authors showed that i.v.
immunization induces immune response of substantially higher
magnitude in liver and spleen than s.c. immunization. In line
with these ﬁndings, and in striking contrast to s.c. vaccination,
i.v. vaccination of human subjects induced sterilizing protection
in 80% of subjects receiving the highest vaccine dose. Moreover,
the protection correlated with numbers of CD8 T cells produc-
ing IFN-γ in a majority of protected subjects. These ﬁndings
demonstrate superior protection induced by i.v. administration
of RAS, and suggest induction of sufﬁcient numbers of antigen-
speciﬁc CD8 T cells as underlying mechanism of the observed
protection.
Together these two studies suggest the translational value
of our main ﬁnding in a mouse malaria model: the impor-
tance of memory CD8 T-cell numbers in sterilizing protec-
tion against liver-stage malaria and the potential existence of
a deﬁnable threshold for sterilizing immunity. Besides being
fundamental ﬁndings of high importance for further improve-
ment of current and development of new malaria vaccine
candidates and vaccination regimens, these ﬁndings also jus-
tify the use of a mouse as a suitable system for studying
basic principles of immunity against pre-erythrocytic malaria
stage.
CONCLUDING REMARKS
In summary, recent information generated in the mouse model of
Plasmodium infection sets the cornerstone for further research
of CD8 T-cell-mediated protection against liver-stage malaria.
The most striking ﬁnding is that induction of extremely high
numbers of memory CD8 T cells is a prerequisite for solid,
sterile protection. Therefore, developing vaccines or vaccina-
tion regimens that will ensure induction of high-magnitude
memory CD8 T-cell response against selected, highly protec-
tive target antigens is one means for successful immunization.
However, it is still not known whether induction of addi-
tional immune components, such as CD4 T cells and anti-
bodies, would positively inﬂuence the protection, for example,
by decreasing the required numbers of CD8 T cells. Addi-
tionally, induction of CD8 T cells speciﬁc for antigens shared
by (late) liver-stage and blood-stage parasite is a promising
approach toward cross-stage, and possibly cross-species protec-
tion. Thus, one focus for future research should be discovery
and characterization of such “shared” epitopes. Finally, the pre-
cise qualitative features leading to optimal memory CD8 T-cell
protection against liver-stage Plasmodium infection remain to be
determined.
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